B
Braidwell Portfolio holdings
AUM
$2.92B
This Quarter Return
+5.34%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$3.53B
AUM Growth
+$3.53B
(+11%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
5.46%
Top 10 Holdings %
Top 10 Hldgs %
34.64%
Holding
91
New
15
Increased
24
Reduced
22
Closed
8
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$72.5M |
| 2 |
Edgewise Therapeutics
EWTX
|
$52.3M |
| 3 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$42.2M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$39M |
| 5 |
Sarepta Therapeutics
SRPT
|
$36M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$58.4M |
| 2 |
Exact Sciences
EXAS
|
$58.3M |
| 3 |
Apogee Therapeutics
APGE
|
$44M |
| 4 |
Thermo Fisher Scientific
TMO
|
$39M |
| 5 |
argenx
ARGX
|
$38.1M |
Sector Composition
| 1 | Healthcare | 65.68% |
| 2 | Consumer Staples | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $120M | 3.39% | 3,170,875 -138,632 | -4% | -$5.23M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $107M | 3.02% | 2,707,255 +146,682 | +6% | +$5.77M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $106M | 3% | 917,674 +158,665 | +21% | +$18.3M |
|
|
4
Apogee Therapeutics
APGE
$2.17B
| $96.5M | 2.74% | 1,643,226 -748,816 | -31% | -$44M |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $90.1M | 2.55% | 3,125,183 +2,513,383 | +411% | +$72.5M |
|
6
Align Technology
ALGN
$10.3B
| $79.3M | 2.25% | 311,679 +36,472 | +13% | +$9.28M |
|
7
Guardant Health
GH
$8.41B
| $76.7M | 2.17% | 3,342,124 +534,156 | +19% | +$12.3M |
|
8
Legend Biotech
LEGN
$6.41B
| $75.1M | 2.13% | 1,541,551 -128,169 | -8% | -$6.25M |
|
9
Viking Therapeutics
VKTX
$3.04B
| $73.2M | 2.08% | 1,156,977 +50,072 | +5% | +$3.17M |
|
10
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $72.3M | 2.05% | 2,894,513 +836,210 | +41% | +$20.9M |
|
11
Penumbra
PEN
$10.6B
| $70.2M | 1.99% | 361,428 +148,834 | +70% | +$28.9M |
|
12
Maravai LifeSciences
MRVI
$350M
| $69.4M | 1.97% | 8,353,287 -670,750 | -7% | -$5.57M |
|
13
Day One Biopharmaceuticals
DAWN
$769M
| $67.9M | 1.92% | 4,873,853 +1,837,949 | +61% | +$25.6M |
|
14
Spyre Therapeutics
SYRE
$996M
| $64.4M | 1.83% | 2,189,836 -324,702 | -13% | -$9.55M |
|
15
Repligen
RGEN
$6.88B
| $59M | 1.67% | 396,781 +73,272 | +23% | +$10.9M |
|
16
iRhythm Technologies
IRTC
$5.46B
| $58.1M | 1.65% | 782,557 +256,200 | +49% | +$19M |
|
|
17
argenx
ARGX
$43.6B
| $52.4M | 1.49% | 96,724 -70,200 | -42% | -$38.1M |
|
|
18
Edgewise Therapeutics
EWTX
$1.51B
| $52.3M | 1.48% | +1,958,310 | New | +$52.3M |
|
19
Inspire Medical Systems
INSP
$2.77B
| $50.4M | 1.43% | 238,911 -140,532 | -37% | -$29.7M |
|
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $46.3M | 1.31% | 370,400 +288,500 | +352% | +$36M |
|
21
Intuitive Surgical
ISRG
$170B
| $44.9M | 1.27% | 91,300 -9,200 | -9% | -$4.52M |
|
|
AVDL
22
Avadel Pharmaceuticals
AVDL
$1.43B
| $44.4M | 1.26% | 3,388,939 +490,300 | +17% | +$6.43M |
|
|
BCAX
23
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $42.2M | 1.2% | +1,657,600 | New | +$42.2M |
|
24
Keros Therapeutics
KROS
$618M
| $41.1M | 1.16% | 707,240 -274,969 | -28% | -$16M |
|
25
Glaukos
GKOS
$5.5B
| $40.6M | 1.15% | 311,616 -184,960 | -37% | -$24.1M |
|